Pyoderma gangrenosum - Pioderma Gangrenoso
El Pioderma Gangrenoso (Pyoderma gangrenosum) es una enfermedad inflamatoria rara de la piel en la que las pústulas o nódulos dolorosos se convierten en úlceras que crecen progresivamente. pioderma gangrenoso (pyoderma gangrenosum) no es infeccioso. Los tratamientos pueden incluir corticosteroides, ciclosporina o varios anticuerpos monoclonales. Aunque puede afectar a personas de cualquier edad, afecta principalmente a personas de entre 40 y 50 años.
☆ En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
En la pierna de una persona con colitis ulcerosa.
References
Pyoderma gangrenosum es una afección cutánea poco común que causa úlceras dolorosas con bordes rojos o violáceos. Se clasifica como una enfermedad inflamatoria y forma parte de un grupo llamado dermatosis neutrofílicas. La causa de pyoderma gangrenosum es compleja e involucra problemas con la inmunidad tanto innata como adaptativa en personas genéticamente propensas. Recientemente, los investigadores se han centrado en el folículo piloso como posible punto de partida de la enfermedad.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum es una afección cutánea poco común que causa úlceras extremadamente dolorosas. Si bien no entendemos completamente su causa, sabemos que implica una mayor actividad de ciertas células inmunes. Tratar la enfermedad todavía no es fácil. Disponemos de diversos fármacos que inhiben el sistema inmunológico o modifican su actividad. Además de esto, también nos centramos en el tratamiento de las heridas y el control del dolor. Los corticosteroides y la ciclosporina suelen ser la primera opción de tratamiento, pero últimamente se han realizado más investigaciones sobre el uso de terapias biológicas como los inhibidores del TNF-α. Estos productos biológicos son cada vez más preferidos, especialmente en pacientes con otras afecciones inflamatorias, y se utilizan en una fase más temprana del proceso de la enfermedad.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
